Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.

Slides:



Advertisements
Similar presentations
Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.
Advertisements

Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.
Atrial Fibrillation Management Past, Present and Future
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Working group 3: How to encourage more minorities.
Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mechanical Thrombectomy for Acute Ischemic Stroke:
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Levels of Neuropeptide Proenkephalin.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inappropriate Implantable Cardioverter-Defibrillator.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic value of coronary artery calcium screening.
Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Fasudil in Patients With.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Reduction in Ventricular Tachyarrhythmias With Statins.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Improved Survival of Patients With End-Stage Heart.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Donor Pre-Treatment With Dopamine on.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effect of Intermittent Atrial Tachyarrhythmia.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Reduction of the Risk of Recurring Heart Failure.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Time to Cost-Effectiveness Following Stroke Reduction.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influenza Vaccination and Vitamin K Antagonist Treatment:
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA/ESC 2006 Guidelines for the Management of.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Health-Related Quality of Life After Carotid Stenting.
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heavy Metals, Cardiovascular Disease, and the Unexpected.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Ventricular Arrhythmia After Cardiac Surgery: Incidence,
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantable Cardioverter-Defibrillators at End of.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Healthy Lifestyle and Decreasing Risk of Heart Failure.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Ethnic Differences in the Prognostic Value of Coronary.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Wearable Cardioverter-Defibrillator Use in Patients.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Date of download: 7/14/2016 Copyright © The American College of Cardiology. All rights reserved. From: Thoracic Aortic Aneurysm and Dissection J Am Coll.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Anticoagulation of Bioprosthetic Aortic Valves.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: What resting heart rate should one aim for when.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Real-Time Dynamic Carbon Dioxide Administration:
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Efficacy of Ivabradine in Patients With.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Risk in Clopidogrel-Treated Patients.
From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the.
Copyright © 2003 American Medical Association. All rights reserved.
Volume 149, Issue 6, Pages (June 2016)
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
Figure 1 Flow chart diagram of high-risk group AF patients
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Nat. Rev. Cardiol. doi: /nrcardio
Selecting NOACs for High-Risk Patients
Presentation transcript:

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation: The ENGAGE AF–TIMI 48 Trial J Am Coll Cardiol. 2014;64(6): doi: /j.jacc End-of-Trial Transition to Open-Label Anticoagulation *There were 12, 11, and 10 patients who transitioned to antiplatelet therapy alone in the warfarin, edoxaban high-dose, and edoxaban low-dose groups, respectively. There were 16, 20, and 11 patients who transitioned to no antithrombotic therapy in the warfarin, edoxaban high-dose, and edoxaban low-dose groups, respectively. Frequent international normalized ratio (INR) testing = at least 3 INR tests performed in days 4 to 14 during the transition phase with continued INR testing days 15 to 30 if vitamin K antagonist (VKA) dose changes or if INR was not in the therapeutic range (2.0 to 3.0). FXa = activated factor X. Figure Legend:

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation: The ENGAGE AF–TIMI 48 Trial J Am Coll Cardiol. 2014;64(6): doi: /j.jacc Stroke or SEE Occurrence of stroke or systemic embolic during the 30-day transition period at the end of the trial. HD = high dose; Hem = hemorrhagic; HR = hazard ratio; Isch = ischemic; LD = low dose; SEE = systemic embolic event. Figure Legend:

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation: The ENGAGE AF–TIMI 48 Trial J Am Coll Cardiol. 2014;64(6): doi: /j.jacc Bleeding Events Occurrence of major bleeding during the 30-day transition period at the end of the trial. Abbreviations as in Figure 2. Figure Legend:

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation: The ENGAGE AF–TIMI 48 Trial J Am Coll Cardiol. 2014;64(6): doi: /j.jacc Cumulative Proportion of Patients Transitioned to Open-Label Vitamin K Anticoagulant With at Least 1 INR ≥2 Within 30 Days From End of Study The X at day 0 represents the percentage of patients with an international normalized ratio (INR) ≥2 at the end-of-trial visit. Patients initially assigned edoxaban, who did not yet have an INR measured after the end-of-trial visit were assumed to have an INR <2.0 during the days between the last study visit and the first post-study INR measurement on day 4 or later. Abbreviations as in Figure 2. Figure Legend:

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation: The ENGAGE AF–TIMI 48 Trial J Am Coll Cardiol. 2014;64(6): doi: /j.jacc Key Components of the End-of-Trial Transition At the end of 2 previous trials, an excess of stroke and bleeding was observed in patients with AF randomized to a new oral anticoagulant (NOAC) who transitioned to a vitamin K antagonist (VKA). In the ENAGE AF-TIMI 48 trial, a transition plan was developed to protect patients transitioning to open-label VKA or an NOAC at the trial’s end by minimizing both the risk of ischemic stroke due to inadequate anticoagulation and the risk of bleeding with excessive anticoagulation while maintaining the integrity of the blinding to the treatment allocation. The end-of-trial transition plan consisted of 4 key components: 1) selection of the oral anticoagulant (VKA or an NOAC) by the treating physician and patient; 2) a 14-day transition kit of modified-dose edoxaban for patients randomized to edoxaban or matching placebo for patients randomized to warfarin; 3) early and frequent international normalized ratio (INR) testing (≥3 tests during the first 2 weeks); and 4) use of a VKA titration algorithm. Figure Legend: